We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Assertio is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Assertio is a member of the Medical sector. This group includes 1161 individual stocks and currently holds a Zacks Sector Rank of #12. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Assertio is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ASRT's full-year earnings has moved 75% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ASRT has moved about 13.8% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 10.8% on average. This means that Assertio is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Homology Medicines (FIXX - Free Report) . The stock has returned 6% year-to-date.
The consensus estimate for Homology Medicines' current year EPS has increased 0.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Assertio belongs to the Medical - Drugs industry, a group that includes 231 individual stocks and currently sits at #156 in the Zacks Industry Rank. On average, this group has lost an average of 13.7% so far this year, meaning that ASRT is performing better in terms of year-to-date returns.
Homology Medicines, however, belongs to the Medical - Generic Drugs industry. Currently, this 17-stock industry is ranked #222. The industry has moved -11% so far this year.
Assertio and Homology Medicines could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
View the Zacks #1 Rank List
Image: Bigstock
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Assertio is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Assertio is a member of the Medical sector. This group includes 1161 individual stocks and currently holds a Zacks Sector Rank of #12. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Assertio is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ASRT's full-year earnings has moved 75% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, ASRT has moved about 13.8% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 10.8% on average. This means that Assertio is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Homology Medicines (FIXX - Free Report) . The stock has returned 6% year-to-date.
The consensus estimate for Homology Medicines' current year EPS has increased 0.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Assertio belongs to the Medical - Drugs industry, a group that includes 231 individual stocks and currently sits at #156 in the Zacks Industry Rank. On average, this group has lost an average of 13.7% so far this year, meaning that ASRT is performing better in terms of year-to-date returns.
Homology Medicines, however, belongs to the Medical - Generic Drugs industry. Currently, this 17-stock industry is ranked #222. The industry has moved -11% so far this year.
Assertio and Homology Medicines could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.